Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 2;29(6):318–329. doi: 10.1007/s12471-021-01539-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Schematic overview of the study design. The BIO FOr CARe (Identification of BIOmarkers of hypertrophic cardiomyopathy development and progression in Dutch MYBPC3 FOunder variant CARriers) study comprises an observational cohort of Dutch carriers of the c.2373dupG (p.Trp792fs), c.2827C > T (p.Arg943Ter), c.2864_2865delCT (p.Pro955fs) and c.3776delA (p.Gln1259fs) variants in the MYBPC3 gene. These variants are predicted to result in truncated mRNA with absence of truncated protein leading to haploinsufficiency. Subjects across the phenotypic spectrum associated with these variants are prospectively included for blood collection every 2 years and followed up over time. Clinical data are retrospectively collected from the first presentation onwards in a clinical registry to assess potential clinical predictors of disease penetrance and progression. HCM hypertrophic cardiomyopathy